You are here: Home » News-CM » Companies » News
Business Standard

Lupin receives USFDA final approval for Hydroxychloroquine Sulfate Tablets

Capital Market 

Lupin has received final approval for its Sulfate Tablets USP, 200 mg from the (FDA) to market a generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg.

Lupin's Sulfate Tablets USP, 200 mg is the generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg.

It is indicated for: - the treatment of uncomplicated due to P. falciparum, P. malariae, P. ovale, and P. vivax

- the prophylaxis of in geographic areas where chloroquine resistance is not reported

- the treatment of erythernatosus and in adults

- the treatment of in adults

Sulfate Tablets USP, 200 mg had annual sales of approximately USD 215.3 million in the US (IQVIA MAT April 2018).

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, July 09 2018. 15:38 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU